Obesity

Chile warning labels on food: new evidence on efficacy and obesity risk

Chile warning labels on food are back in focus as new reporting adds child obesity data to an established evidence base on purchase shifts. For B2B readers, the key question is whether Chile food labels continue to shape regulation, consumer behavior, and adjacent policy debates.

AstraZeneca expands obesity push as it invests $125M in ultrasound medicine

AstraZeneca’s obesity strategy widened after newly published data supported a sprawling late-stage program for its GLP-1 pill. The company also committed $125 million to ultrasound-aided genetic medicine, signaling continued platform investing.

Obesity rates in America by year: what the data shows

This analysis summarizes obesity rates in America by year using the strongest available public-health data and explains why the trend matters for pharma BD and investors. It also places U.S. prevalence in the context of global obesity statistics and the standard BMI definition.

MariTide Phase 2 obesity data show up to 20% weight loss at one year

Amgen’s MariTide phase 2 obesity data showed up to 20% average weight loss at 52 weeks in participants without type 2 diabetes. The trial also reported up to 17% average weight loss in participants with type 2 diabetes, with placebo results provided in the published data.

Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win

Pfizer said its oral GLP-1 danuglipron met the primary endpoint in a Phase 2b obesity trial, showing a statistically significant change in body weight from baseline. The result strengthens the case for Pfizer's oral GLP-1 strategy and sets up investor and BD scrutiny around Phase 3 design, safety, and differentiation.

Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint

Pfizer said danuglipron, its oral GLP-1 receptor agonist, met the primary endpoint in a Phase 2b obesity trial with statistically significant weight loss versus baseline. The result strengthens the case for Danuglipron Phase 3 planning and gives BD and investor teams a fresh benchmark against other oral GLP-1 programs.

Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update

Novo Nordisk’s CagriSema phase 3 update shows strong obesity and diabetes efficacy, but the obesity readout fell short of top-tier expectations. This plan focuses on the catalyst, the comparator data, and what BD teams and investors should watch next.

Design Therapeutics' Friedreich's Ataxia Data and Vincentage's Obesity Results: A Strategic Analysis

Design Therapeutics presents new data on its Friedreich's Ataxia program, while Vincentage reports significant obesity treatment outcomes from China. These developments offer critical insights for pharmaceutical BD, strategy, and investment teams.